Avalyn Pharma Inc.
AVLN · Nasdaq · United States
Share price · AVLN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when AVLN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+5.7%
Nothing announced by AVLN that day or the session before.
- 6 Nov 2026+9.3%
Nothing announced by AVLN that day or the session before.
- 27 Oct 2026-4.8%
Nothing announced by AVLN that day or the session before.
- 22 Oct 2026+8.5%
Nothing announced by AVLN that day or the session before.
- 17 Jul 2026+10.2%
Nothing announced by AVLN that day or the session before.
Share of unusual movement by asset
For each asset, the share of AVLN's own-move activity since 1 May 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 12% |
| Sessions with no dated event | — | 88% |
No dated announcements about its assets since 1 May 2026.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Mechanism not establishedSmall molecule | Indication not yet linked |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
June 2027 (1)
What to watch
2031 (1)
December 2031 (1)
What to watch
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $25M | $145M+ $182M short-term inv. | $30M-$26M operating cash flow | report ↗ |
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $25M | $264M+ $88M short-term inv. | $29M-$26M operating cash flow | report ↗ |
| 2026-Q1 | — | $23M | $92M+ $31M short-term inv. | $27M-$30M operating cash flow | report ↗ |
| 2025-Q3 | — | $22M | $28M | $24M-$17M operating cash flow | report ↗ |
| 2025-Q2 | — | $18M | $61M | $20M-$21M operating cash flow | report ↗ |
| 2025-Q1 | — | $15M | $29M | $18M-$19M operating cash flow | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $52M+ $86M short-term inv. | — | report ↗ |
Avalyn Pharma Inc. reported cash and equivalents of $52.32M for fiscal year 2025.
Figures only: this period's report disclosed no narrative text
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | — | $24M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 4 purchases ($25.0M), 18 sales ($9.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | Baranowski Lyn · director, Chief Executive Officer | Option exercise | 7,200 | $4.62 | $33K | Form 4 |
| 2026-11-18 | Baranowski Lyn · director, Chief Executive Officer | Open-market sale | 6,465 | $27.90 | $180K | Form 4 |
| 2026-11-18 | Baranowski Lyn · director, Chief Executive Officer | Open-market sale | 735 | $28.36 | $21K | Form 4 |
| 2026-11-18 | Baranowski Lyn · director, Chief Executive Officer | Option exercise (derivative) | 7,200 | — | — | Form 4 |
| 2026-11-17 | Carlson Douglas R · See Remarks | Option exercise | 14,875 | $4.62 | $69K | Form 4 |
| 2026-11-17 | Rhodes Melissa · Chief Operating Officer | Option exercise | 13,300 | $4.62 | $61K | Form 4 |
| 2026-11-17 | Baranowski Lyn · director, Chief Executive Officer | Option exercise | 45,300 | $4.62 | $209K | Form 4 |
| 2026-11-17 | Lazarus Howard · Chief Medical Officer | Option exercise | 13,300 | $4.62 | $61K | Form 4 |